Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385788 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00385788: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00385788 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00385788, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if fludarabine, melphalan and gemcitabine followed by transplantation of stem cells (blood-forming cells) as well as immune cells (lymphocytes), collected from a matched related (i.e. a sibling) or unrelated donor, or a mismatched related donor, can help to control Hodgkin's disease. The safety of the treatment will also be studied.
Primary Outcome
Transplant-related mortality defined as death from any cause in the first 100 days post-transplant in patients without active disease.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Gemcitabine
- PROCEDURE Allogeneic Stem Cell Infusion
- DRUG Antithymocyte Globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2005-07 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
What the finished NCT00385788 record still lists
NCT00385788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00385788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00385788 about?
NCT00385788 is a clinical study titled "Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease". The goal of this clinical research study is to learn if fludarabine, melphalan and gemcitabine followed by transplantation of stem cells (blood-forming cells) as well as immune cells (lymphocytes), collected from a matched related (i.e. a sibling) or unrelated donor, or a mismatched related donor, c...
What is the current status of trial NCT00385788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2005-07. Estimated completion is 2016-08.
What interventions are being tested in trial NCT00385788?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Gemcitabine (DRUG), Allogeneic Stem Cell Infusion (PROCEDURE), Antithymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT00385788?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00385788's enrollment target sits among peer trials
52 1181st of 2000 higher than 811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia